RANIBIZUMAB

ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe

RANIBIZUMAB (13166Y)

ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe
13166Y
Manner of administration:Injection
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 13387)

Indication: Branch retinal vein occlusion with macular oedema
Treatment phase: Continuing treatment

Restriction (Streamlined authority code: 13336)

Indication: Central retinal vein occlusion with macular oedema
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $786.69 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucentis